- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02800889
Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer
January 27, 2020 updated by: CTI BioPharma
A Phase 1, Dose-Escalation Study of Pixantrone Monotherapy in Pediatric Patients With Relapsed or Refractory Cancer
This is a phase 1, open-label, dose escalation study to evaluate the safety, pharmacokinetics, and antitumor activity of pixantrone in pediatric patients with relapsed or refractory solid tumors (excluding those with CNS tumors) or lymphoma.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
Approximately thirty-five eligible patients will receive up to six 28-day cycles of pixantrone monotherapy, with two additional cycles in patients who continue to benefit from treatment.
Each patient will receive pixantrone administered intravenously on days 1, 8, and 15 of each 28-day cycle.
There will be three age cohorts, defined as age cohort 1 (12 to less than 18 years, plus young adults (ages 18-21 years)), age cohort 2 (5 to less than 12 years), and age cohort 3 (6 months to less than 5 years).
During dose escalation, three patients will first be accrued to the starting dose level.
If no DLTs are identified, that dose level will be declared to not exceed the MTD and three patients will be accrued to the next higher dose level.
Each subsequent dose-escalation level will be accrued per the DLT/MTD determination schema above.
Planned sequential dose-escalation phase will receive 40 mg/m2, 50 mg/m2, 60 mg/m2 or 70 mg/m2 of pixantrone base (on days 1, 8 and 15), as tolerated, based on DLT evaluation.Dose escalations will follow a standard 3+3 patient cohort escalation plan.
No patients from Age Cohort 3 will be enrolled until 6 patients from age cohorts 1 and 2 (combined) are evaluable for toxicity.
After the MTD has been determined, an expansion phase will be accrued in order to gain better estimates of the safety, tolerability, and anti-tumor activity of pixantrone monotherapy in pediatric patients when treated at the MTD.
Patients will be offered 3 years of post-study extension phase follow-up with periodic assessments of cardiac function parameters.
Study Type
Interventional
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
California
-
Los Angeles, California, United States, 90027
- Children's Hospital Los Angeles
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
6 months to 21 years (Child, Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Patient and/or guardian have signed an Informed Consent Form and Assent approved by the Institutional Review Board or Institutional Ethics Committee, as appropriate and necessary, on a per-age basis
- Age 6 months to 21 years old (initial qualifying diagnosis must have been made at or before the age of 18 and the patient must be under the care of a pediatric hematologist/oncologist)
- Patient received a diagnosis of lymphoma or any non-hematologic malignancy (except central nervous system [CNS] tumors) for which the patient is considered relapsed or refractory. (NOTE: CNS metastases are allowable in patients who are deemed not at risk for progression during the first 30 days, who are neurologically stable, and, if on corticosteroids, have been on a stable corticosteroid dose for at least 2 weeks.) Patients who have >1 malignancy ongoing during screening are not eligible
Patient must have one or more of the following treatment statuses:
- Has failed at least 2 prior lines of chemotherapy
- Has no curative chemotherapy treatment option available
- Is not considered a candidate for available chemotherapy treatment options
- In dose-escalation accrual, patients may have un-measurable disease (such as bone marrow/bone involvement or diffuse tumors)
- In dose-escalation accrual, patients may have un-measurable disease in cases where the standard of care would indicate the need for adjuvant chemotherapy after definitive surgery or radiation, but for whom no standard chemotherapy options are available
- In expansion cohort accrual, patients must have disease that is evaluable or measurable for response and progression per standard criteria for their diagnosis (Refer to the Appendices: RECIST 1.1 Criteria for Evaluation of Solid Tumors, Including Neuroblastoma, Appendix 18.4], Evaluation of Neuroblastoma [Appendix 18.6], and the Lymphoma Staging and Disease Response Criteria [Appendix 18.5])
- Karnofsky-Lansky performance status (as per age of patient) ≥50 (Appendix 18.1)
Patient must have one or more of the following cardiac function measurements by echocardiogram:
- Left ventricular ejection fraction (LVEF) ≥55%
- Left ventricular shortening fraction (LVSF) ≥27%
- Hemoglobin ≥8 g/dL (can be post-transfusion)
- Platelet count ≥75 × 109/L
- Absolute neutrophil count (ANC) ≥0.75 × 109/L
- Serum direct/conjugated bilirubin ≤1.5 × upper limit of normal (ULN); patients with clinically diagnosed Gilbert's syndrome and total bilirubin ≤5 × ULN may be enrolled
- Aspartate aminotransferase (AST; also called serum glutamic-oxaloacetic transaminase [SGOT]) and alanine aminotransferase (ALT; also called serum glutamic-pyruvic transaminase [SGPT]) ≤2.5 × ULN, or ≤5 × ULN if elevation is due to hepatic involvement by tumor
- Serum creatinine ≤2 × ULN
Patients must meet the following criteria with respect to prior cancer therapy, radiotherapy, and stem cell transplants:
- Myelosuppressive chemotherapy: At least 3 weeks must have elapsed since the completion of myelosuppressive chemotherapy (4 weeks if prior nitrosourea) and resolution of all nonhematologic toxicities to ≤grade 1.
Biologic (anti-neoplastic agent):
- Oral tyrosine kinase inhibitors or other similar agents. At least 7 days must have elapsed since the completion of therapy with a biologic agent and all non-hematologic toxicities must have resolved to ≤grade 1 prior to enrollment
- Anti-IGFR-1R and other monoclonal antibodies: the shorter of 3 half-lives or 6 weeks must have elapsed since previous monoclonal antibody therapy and resolution of all non-hematologic toxicities to ≤grade 1 prior to enrollment
- Myeloid Growth Factor: Must not have received within 1 week prior to entry into this study (2 weeks in the case of PEG-filgrastim)
- Radiotherapy: At least 4 weeks must have elapsed and all non-hematologic toxicities must have resolved to ≤grade 1 prior to enrollment. Previously radiated lesions cannot be used to assess response unless those sites are the sites of disease progression
- Stem cell transplant (SCT): For autologous SCT, ≥3 months must have elapsed. For allogeneic SCT, ≥6 months must have elapsed and there must be no evidence of active graft versus host disease
- All acute toxicities related to prior treatment recovered to grade ≤1 , except alopecia and hematologic parameters specified in the inclusion criteria
- Willingness and ability to comply with the visit schedule and assessments required by the study protocol, including effective birth control (Section 5.4) for sexually active patients
Exclusion Criteria:
- Investigator-predicted life expectancy of less than two months
- Investigator-predicted inability to tolerate pixantrone monotherapy treatment adverse effects for less than two months
- Prior anthracycline treatment with a cumulative dose exceeding 450 mg/m2 (calculated based on doxorubicin equivalents)
- Active National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) ≥grade 3 infection, or a lower grade infection deemed resistant or refractory to available antimicrobial agents, or infection requiring ongoing antibiotic treatment
- Major surgery ≤7 days and/or with incomplete/inadequate wound healing prior to start of study treatment
- Known acute or chronic hepatitis B or hepatitis C virus infection
- Known seropositivity for human immunodeficiency virus (HIV)
- Any experimental/investigational therapy ≤28 days prior to start of study treatment
- Myocardial infarction within the past 6 months
- New York Heart Association class II, III or IV heart failure
- Any contraindication, known allergy, or hypersensitivity to any investigational drug(s)
- Pregnant or lactating
- Planned radiotherapy or surgical procedures for the qualifying malignancy
- Any psychological, familial, sociological, or geographical condition potentially hampering compliance with the study procedures or follow-up schedules
- Other severe and/or uncontrolled medical disease that could compromise participation in the study, or any medical or psychiatric condition that, in the opinion of the investigator, would make study drug administration hazardous or obscure the interpretation of data
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment: Pixantrone
Each patient will receive pixantrone monotherapy administered intravenously once on days 1, 8, and 15 up to six 28-day cycles of pixantrone monotherapy, with two additional cycles in patients who continue to benefit from treatment.
At least 6 patients each from Age Cohorts 1 and 2 will be accrued into dose escalation cohorts.
The study will be opened to patients of Age Cohort 3 only after at least 6 patients in Age Cohorts 1 and 2 (combined) have been evaluated for toxicity.
During the dose escalation phase, participants who are inevaluable for DLT for reasons unequivocally unrelated to toxicity will be replaced.
Expansion cohort accrual quota-At least 15 evaluable patients treated with the MTD/optimal dose will be accrued in total, of which 7 patients will be in Age Cohort 2.
|
Pixantrone
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
MTD, defined as the highest dose level at which no more than 1/6 patients experience DLT
Time Frame: 28 days
|
Dose Escalation- The study will follow a standard 3+3 patient cohort escalation design, evaluating up to 4 dose levels.
|
28 days
|
Anti-tumor activity of pixantrone at the MTD
Time Frame: approx. 1 year
|
Dose Expansion Cohort- Anti-tumor activity will be summarized by disease type, dose level, and age cohort for all patients in the evaluable population.
The best overall response rate, defined as the proportion of patients that achieved a complete or partial response, will be summarized by disease type and a 95% confidence interval will be provided.
A similar summary will be provided for the complete response rate.
|
approx. 1 year
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Leo Mascarenhas, MD. MS., CHLA
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
October 24, 2016
Primary Completion (Actual)
July 10, 2018
Study Completion (Actual)
July 10, 2018
Study Registration Dates
First Submitted
June 3, 2016
First Submitted That Met QC Criteria
June 14, 2016
First Posted (Estimate)
June 15, 2016
Study Record Updates
Last Update Posted (Actual)
January 29, 2020
Last Update Submitted That Met QC Criteria
January 27, 2020
Last Verified
January 1, 2020
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- PIX111
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lymphoma
-
Marcela V. Maus, M.D.,Ph.D.RecruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Non-Hodgkin Lymphoma | Primary Mediastinal Large B-cell Lymphoma (PMBCL) | Non-hodgkin Lymphoma | High-grade B-cell Lymphoma | Grade 3b Follicular Lymphoma | Relapsed Non-Hodgkin LymphomaUnited States
-
IGM Biosciences, Inc.ADC Therapeutics S.A.Active, not recruitingFollicular Lymphoma | Mantle Cell Lymphoma | Marginal Zone Lymphoma | Non-Hodgkin Lymphoma | DLBCLUnited States, Korea, Republic of, Spain, France, Australia, Czechia, Italy
-
Novartis PharmaceuticalsBristol-Myers SquibbRecruitingNon-Hodgkin Lymphoma, Diffuse Large B Cell Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Marginal Zone LymphomaUnited States, Germany, Italy, Korea, Republic of, Spain, Singapore, China, Japan, Australia
-
SymBio PharmaceuticalsCompletedFollicular Lymphoma | Non-Hodgkin's Lymphoma | Lymphoma, Large Cell | Diffuse, Mantle Cell Lymphoma, Lymphoma | Large B-Cell, DiffuseJapan, Korea, Republic of
-
University of WashingtonAstraZenecaRecruitingB-Cell Non-Hodgkin Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | High Grade B-Cell Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular Lymphoma | Diffuse Large B-Cell Lymphoma, Not Otherwise Specified | Transformed Follicular Lymphoma to Diffuse...United States
-
Iksuda Therapeutics Ltd.RecruitingFollicular Lymphoma | B-cell Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | B-cell Non-Hodgkin LymphomaAustralia, Canada, United States
-
Epizyme, Inc.CompletedFollicular Lymphoma | Marginal Zone Lymphoma | Advanced Solid Tumors | Mantle-Cell Lymphoma | Diffuse Large B Cell Lymphoma | Primary Mediastinal LymphomaUnited Kingdom
-
Robert LowskyNational Cancer Institute (NCI); Janssen, LP; The Leukemia and Lymphoma Society; Rising Tide FoundationCompletedMantle Cell Lymphoma | Marginal Zone Lymphoma | Recurrent Follicular Lymphoma | Refractory Follicular Lymphoma | Grade 1 Follicular Lymphoma | Grade 2 Follicular Lymphoma | Grade 3a Follicular LymphomaUnited States
-
Zhejiang UniversityShanghai First Song Therapeutics Co., LtdNot yet recruitingHodgkin Lymphoma | Anaplastic Large Cell Lymphoma | Angioimmunoblastic T-cell Lymphoma | Diffuse Large B Cell Lymphoma | Gray Zone Lymphoma | NK/T Cell Lymphoma | Peripheral T Cell Lymphoma, Unspecified | Mediastinal B-Cell Diffuse Large Cell LymphomaChina
-
Massachusetts General HospitalVarian Medical SystemsNot yet recruitingLymphoma, B-Cell | Follicular Lymphoma | Mantle Cell Lymphoma | Diffuse Large B Cell Lymphoma | Refractory Lymphoma | High-grade B-cell Lymphoma | Relapsed Cancer | Mediastinal Large B-cell LymphomaUnited States
Clinical Trials on Pixantrone
-
CTI BioPharmaCompletedAcute Myelogenous LeukemiaUnited States
-
Alliance for Clinical Trials in OncologyNational Cancer Institute (NCI)CompletedBreast CancerUnited States
-
Johannes Gutenberg University MainzRoche Pharma AG; ServierCompleted
-
CTI BioPharmaTerminatedLymphoma, Follicular | Lymphoma, Mixed-Cell, Follicular | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Low-GradeUnited States
-
Anne Beaven, MDCTI BioPharmaCompletedNon-Hodgkin's LymphomaUnited States
-
CTI BioPharmaCompletedDiffuse Large B-cell Lymphoma | de Novo DLBCL | DLBCL Transformed From Indolent Lymphoma | Follicular Grade 3 LymphomaUnited States, Germany, Italy, United Kingdom, Hungary, France, Spain, Ukraine, Czechia, Austria, Belgium, Bulgaria, Denmark, Poland, Romania, Russian Federation, Slovakia
-
CTI BioPharmaWithdrawnLymphoma | LeukemiaUnited States
-
CTI BioPharmaWithdrawnNon-Hodgkin's LymphomaUnited States
-
CTI BioPharmaWithdrawnMetastatic CancerUnited States
-
CTI BioPharmaCompletedLymphoma, Mixed-Cell, Follicular | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Low-Grade | Lymphoma, Small LymphocyticUnited States